[January 13, 2012]

Research and Markets: The VTE Therapeutics Market is Forecast to Show Significant Growth Until 2018

Research and Markets(http://www.researchandmarkets.com/research/db02ae/venous_thromboembo) has announced the addition of GlobalData 's new report "Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

GlobalData, the industry analysis specialist, has released its new report, Venous Thromboembolism (VTE) Therapeutics - Pipeline Assesment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Venous Thromboembolism Therapeutics market. The report identifies the key trends shaping and driving the global Venous Thromboembolism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.

The VTE Therapeutics Market is Forecast to Show Significant Growth Until 2018

GlobalData's analysis suggests that the global VTE therapeutics market was worth $2.9 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% for the next eight years, to reach $5.1 billion by 2018. The global VTE therapeutics market is being driven by the launch of new and efficacious treatment options and an increasing incidence rate. The growth will be further augmented by the increasing uptake of oral factor Xa inhibitor in treatment, and advancements in efficient and accurate diagnostic tools and techniques. For past many years, warfarin, vitamin K antagonists supplied as Coumadin by Bristol-Myers Squibb's and generics was the only oral anticoagulants available. But limitation with such oral anticoagulant (OAC) drug is they require dose modification based on patient monitoring. The OAC that are expected to launch in near future will offer significant advantages over currently available OAC drug.

Key Topics Covered:

• List of Tables and Figures
• Venous Thromboembolism (VTE) Therapeutics - Introduction
• VTE Therapeutics - Market Characterization
• VTE Therapeutics Market - Competitive Assessment
• VTE Therapeutics Market - Pipeline Assessment
• VTE Therapeutics - Clinical Trials Mapping
• VTE Therapeutics - Strategic Assessment
• VTE Therapeutics - Future Players
• VTE Therapeutics - Acquisition Deals
• VTE Therapeutics Market - Appendix

Companies Mentioned:

• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• Daiichi Sankyo
• Pfizer Inc.
• Sanofi

For more information visit http://www.researchandmarkets.com/research/db02ae/venous_thromboembo

[ Back To TMCnet.com's Homepage ]